Sanofi Shifts Capital to R&D, Boosting Long‑Term Growth Amid Steady EarningsSanofi shifts capital to R&D, easing short‑term earnings but boosting long‑term oncology and rare‑disease pipeline growth.SANOFI Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated Dr. Michael Chen 03/06/2026, 07:38 4 minutes to read
